8 Results for "

CD4 CD25

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "CD4 CD25" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P1684
CAS No.: 1319725-20-6
Synonyms: FOXP3 inhibitor P60
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
loading...
    loading...
Cat. No.: HY-W181026
CAS No.: 1197834-98-2
Target:  

Fluorescent Dye

Research Areas:  

Inflammation/Immunology

KLF10-IN-1 (#48-15) is a KLF10 inhibitor with an IC50 value of 40 μM for KLF10 reporter gene. KLF10-IN-1 can inhibit KLF10-DNA binding and transcriptional activity, block the conversion of CD4+CD25 T cells to CD4+CD25+T regulatory cells, and inhibit the expression of KLF10 target genes. KLF10-IN-1 can be used as a useful mechanistic probe to study KLF10-mediated effects and T regulatory cell biology .
loading...
    loading...
Cat. No.: HY-P991110

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
loading...
    loading...
Cat. No.: HY-159123
Target:  

MAP4K

Research Areas:  

Cancer

KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
loading...
    loading...
Cat. No.: HY-K0360

MCE Mouse CD4+ CD25+ Regulatory T Cell Positive Selection Kit is designed for the isolation of CD4+ CD25+ regulatory T cells (Tregs) from mouse splenic single-cell suspensions. The kit utilizes a two-step isolation strategy. First, CD4 Enrichment Beads are used to deplete non-target cells and enrich CD4+ T cells. Subsequently, CD25 Capture Antibody specifically binds to CD25+ cells, which are then captured by Releasable Magnetic Beads. Following isolation, the magnetic beads are gently detached from the cell surface using Magnetic Beads Release Buffer, yielding label-free CD4+ CD25+ regulatory T cells with no residual magnetic beads.

loading...
    loading...
Cat. No.: HY-161255
CAS No.: 2117759-07-4
Target:  

NO Synthase

Research Areas:  

Inflammation/Immunology

3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4 +CD25 + T cells expression . 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide .
loading...
    loading...
Cat. No.: HY-P992519
Synonyms: ADWA-11

Research Areas:  

Cancer

PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8 + T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4 +CD25 + T cells on the cytotoxic activity of tumor CD8 + T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P11490
Target:  

MDM-2/p53

Research Areas:  

Inflammation/Immunology Cancer

DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic T cells and suppressing CD4 +/CD25 + regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
loading...
    loading...